A Catalyst For Medicine Innovation: SLA 3D Printing Technology for the Bladder-Related Recurring Illness

The Constantly Evolving New 3D Printing Technology V.S. Traditional Surgery

Instead of oral medication, an in-time, effective, and direct drug delivery on a certain cavity will always post a more promising and faster healing effect when it comes to some treatments of severe recurring illness. For instance, it requires urgent surgery for any form of organ cancer, including a stubborn bladder illness. Yet concerns persist while traditional surgery possesses some operative risks, their cases are often complex with many factors to consider. To that end, technically, it is imperative to call out an innovation.

Drug-delivery System of 3D Printer

Recently, researchers at the University College London (UCL) have developed an innovative 3D printer cooperating with FabRx, a leading expert in the pharmaceutical 3D printing area. The printer, as it is reported, will offer a constant delivery of medicine into the bladder. Using stereolithography (SLA), the researchers have created the device for intra-bladder treatment – administering drugs to the bladder through a catheter – to provide an alternative to oral medication for the treatment of severe bladder disease.

The Producing Process of Bladder Devices 3D Printing

3D Printing Devices for the Intravesical Drug Delivery

The scientists used SLA and an elastic resin to create two bladder devices, one solid and the other hollow, which were designed to be inserted into the bladder through a urethral catheter. Prior to printing, the resin was loaded with three drug loads of lidocaine hydrochloride, a drug commonly used to treat cystitis and mitigate bladder pain. The device is able to change its shape in order to pass through the catheter, showing good resistance to compressive and tensile forces. Once it is inserted into one’s body or removed, it can remain in its original shape.

The Hollow Bladder Device (Left) and the Solid One (Right)

In terms of drug release, studies have shown that the complete release of lidocaine from a hollow device can be completed within four days, while a solid device allows for sustained drug release for up to 14 days.

This innovative medical treatment, as far as we can predict, bodes well for the upcoming future, while providing a good alternative in the intravesical drug delivery process.

Written By

More From Author

You May Also Like